Search results
Results From The WOW.Com Content Network
High-grade prostatic intraepithelial neoplasia (HGPIN) is an abnormality of prostatic glands and believed to precede the development of prostate adenocarcinoma (the most common form of prostate cancer). [1] [2] It may be referred to simply as prostatic intraepithelial neoplasia (PIN).
Together with other parameters, it is incorporated into a strategy of prostate cancer staging which predicts prognosis and helps guide therapy. A Gleason score is given to prostate cancer based upon its microscopic appearance. [1] Cancers with a higher Gleason score are more aggressive and have a worse prognosis. Pathological scores range from ...
Mitoses (also seen in for example high-grade prostatic intraepithelial neoplasia (HGPIN) and prostate inflammation). [4] Prominent nucleoli [4] Intraluminal eosinophilic secretion [4] Intraluminal blue mucin [4]
Medical calculators arose because modern medicine makes frequent use of scores and indices that put physicians' memory and calculation skills to the test. [2] The advent of personal computers, the Internet and Web, and more recently personal digital assistants (PDAs) have formed an environment conducive to their development, spread and use.
Prostate cancer prognosis depends on how far the cancer has spread at diagnosis. Most men diagnosed have low-risk tumors confined to the prostate; 99% of them survive more than 10 years from their diagnoses. Tumors that have metastasized to distant body sites are most dangerous, with five-year survival rates of 30–40%.
However, high magnification (right image) shows the key feature of prominent nucleoli (visible at 200x magnification to make the diagnosis of "high-grade"), as well as other typical features of HGPIN. Reference for features: - Margaret Sanders, M.B.B.Ch., Murali Varma, M.B.B.S.. High grade prostatic intraepithelial neoplasia (HGPIN).
Five-year survival rates can be used to compare the effectiveness of treatments. Use of five-year survival statistics is more useful in aggressive diseases that have a shorter life expectancy following diagnosis, such as lung cancer , and less useful in cases with a long life expectancy, such as prostate cancer .
A panel of epigenetic methylation marker has been explored for prognosis of ovarian cancer, and it is reported that the panel exhibited high specificity and sensitivity (both above 70%) as a screen marker. [5] Epigenetic markers have also shown promising potential as prognostic markers for bladder cancer. [6]